Department of Molecular and Human Genetics, Baylor College of Medicine, Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, Texas, USA.
J Neurochem. 2019 Mar;148(5):573-589. doi: 10.1111/jnc.14564. Epub 2018 Oct 18.
This review focuses on the pathways that regulate lysosome biogenesis and that are implicated in numerous degenerative storage diseases, including lysosomal storage disorders and late-onset neurodegenerative diseases. Lysosomal proteins are synthesized in the endoplasmic reticulum and trafficked to the endolysosomal system through the secretory route. Several receptors have been characterized that execute post-Golgi trafficking of lysosomal proteins. Some of them recognize their cargo proteins based on specific amino acid signatures, others based on a particular glycan modification that is exclusively found on lysosomal proteins. Nearly all receptors serving lysosome biogenesis are under the transcriptional control of transcription factor EB (TFEB), a master regulator of the lysosomal system. TFEB coordinates the expression of lysosomal hydrolases, lysosomal membrane proteins, and autophagy proteins in response to pathways sensing lysosomal stress and the nutritional conditions of the cell among other stimuli. TFEB is primed for activation in lysosomal storage disorders but surprisingly its function is impaired in some late-onset neurodegenerative storage diseases like Alzheimer's and Parkinson's, because of specific detrimental interactions that limit TFEB expression or activation. Thus, disrupted TFEB function presumably plays a role in the pathogenesis of these diseases. Multiple studies in animal models of degenerative storage diseases have shown that exogenous expression of TFEB and pharmacological activation of endogenous TFEB attenuate disease phenotypes. These results highlight TFEB-mediated enhancement of lysosomal biogenesis and function as a candidate strategy to counteract the progression of these diseases. This article is part of the Special Issue "Lysosomal Storage Disorders".
这篇综述重点介绍了调节溶酶体生物发生的途径,这些途径与许多退行性贮积病有关,包括溶酶体贮积病和迟发性神经退行性疾病。溶酶体蛋白在内质网中合成,并通过分泌途径运输到内溶酶体系统。已经鉴定出几种受体,它们执行溶酶体蛋白的高尔基后运输。其中一些受体基于特定的氨基酸特征识别其货物蛋白,而另一些受体则基于仅在溶酶体蛋白上发现的特定糖基化修饰。几乎所有参与溶酶体生物发生的受体都受转录因子 EB(TFEB)的转录控制,TFEB 是溶酶体系统的主要调节因子。TFEB 协调溶酶体水解酶、溶酶体膜蛋白和自噬蛋白的表达,以响应感应溶酶体应激和细胞营养状况等刺激的途径。TFEB 在溶酶体贮积病中被激活,但令人惊讶的是,它在某些迟发性神经退行性贮积病(如阿尔茨海默病和帕金森病)中的功能受损,这是由于特定的有害相互作用限制了 TFEB 的表达或激活。因此,TFEB 功能的破坏可能在这些疾病的发病机制中起作用。退行性贮积病动物模型的多项研究表明,TFEB 的外源性表达和内源性 TFEB 的药理学激活可减轻疾病表型。这些结果强调了 TFEB 介导的溶酶体生物发生和功能增强作为对抗这些疾病进展的候选策略。本文是“溶酶体贮积病”特刊的一部分。